Moreover, its involvement in drug resistance pathways, such as the modulation of PD-L1 expression in gastric cancer and the stabilization of immune checkpoint proteins in neuroblastoma, positions NUTM2A-AS1 as a potential target for novel therapeutic interventions. This evidence concerns the gene NUTM2A and gastric cancer.